Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

re, for gross proceeds of $16,867,200.

At July 31, 2008, 2007 and 2006, the total number of common shares issued and outstanding was 46,375,335, 36,335,335 and 32,685,335, respectively, and the Company's working capital was $19,144,000, $11,468,000 and $10,900,000, respectively.

On October 2, 2008, the Company announced the completion of a private placement, issuing 6,800,000 units at $1.68 per unit, for gross proceeds of $11,424,000. Each unit consists of one common share and one-half common share purchase warrant with each whole common share purchase warrant entitling the holder to purchase one common share at a price of $2.36 until October 1, 2011.

Based on our planned expenditures and assuming no unanticipated expenses, we believe that our cash reserves and expected cash from operations will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for the next 12 months. The Company has no external sources of liquidity such as lines of credit. At present, the Company considers that it will be necessary to conclude one or more debt or equity financings in the near term to be able to continue with its existing business plan. There can be no assurance that any such financing will be available on acceptable terms or at all.

The Company's consolidated fiscal 2008, 2007 and 2006 financial statements are summarized below:

Consolidated Statements of Operations

(thousand $, except for per share data)

---------------------------------------

2008 2007 2006

------------------------

Revenue:

Product revenue 2,952 2,764 3,012

License fees & royalties 639 512 773

Research and

Development contracts - 148 180

------------------------

3,591
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... ANNAPOLIS, Maryland , 15. September 2014 /PRNewswire/ ... Week (IPAW) wird vom 12. bis 18. ... der Plasma Protein Therapeutics Association (PPTA) ... Ziele: , Das globale Bewusstsein für ... Den Beitrag von Plasmaspendern beim Retten und Verbessern ...
(Date:9/14/2014)... September 15, 2014 UMBC’s Biotechnology ... on Tuesday, October 21, 2014, from 12:00 to 1:00 ... the program’s innovative curriculum and practice-oriented instruction, designed for ... degree can help advance their career in the biotechnology ... online . , About UMBC’s Biotechnology Graduate Programs, ...
(Date:9/12/2014)... AMSTERDAM , Sept. 12, 2014   Arthur ... startup bio-bean, has won the Postcode Lottery Green Challenge ... awarded Kay euro 500,000 ($680,000 USD) at the final ... green business plan. Kay,s company uses ... advanced biofuel products, namely biodiesel and biomass pellets, used ...
(Date:9/12/2014)... 12, 2014 Sandia Biotech, Inc. announced ... agreement with STC.UNM (STC) for a technology developed by ... Albuquerque, New Mexico, and Queen Mary University of London ... the Recombinant Fluorescent Antibody Technology Platform (RFAP) was developed ... Medicine and Dr. Angray Kang from Queen Mary’s Department ...
Breaking Biology Technology:International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 2Green Startup Bio-Bean Wins $680,000 in Postcode Lottery Green Challenge 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 4
... Corporation,s (Amex: ETC ) ("ETC" or the ... two (2) BARA-MED(R),Monoplace Hyperbaric Chambers at East Orange ... is a fully accredited, acute care hospital,located in ... of East Orange,General Hospital is run by Dr. ...
... of Enrollment in U.S. Phase II Study,of Nitazoxanide ... TAMPA, Fla., Oct. 28 Romark Laboratories, ... of studies,of nitazoxanide at the upcoming 59th Annual ... Liver Diseases (AASLD), also known as The,Liver Meeting(R), ...
... N.J., Oct. 28 BioWa, Inc. announced ... with KaloBios Pharmaceuticals, Inc.,under which BioWa licenses ... antibody-dependent cellular cytotoxicity (ADDC) of select,KaloBios therapeutic ... strategic partnership with KaloBios,",commented Dr. Masamichi Koike, ...
Cached Biology Technology:Environmental Tectonics Corporation's BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital 2Environmental Tectonics Corporation's BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital 3Environmental Tectonics Corporation's BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital 4Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2BioWa Announces License of Biowa's Potelligent(R) Technology to KaloBios Pharmaceuticals 2
(Date:9/15/2014)... wild, domesticated, and domesticated-wild hybridized populations of ... that within 5 to 11 generations, selection ... populations that hybridized with domesticated populations. , ... evidence that natural selection, over time, removes ... as a result of increased genetic diversity. ...
(Date:9/15/2014)... Ebola virus outbreak in West Africa, which has claimed ... a deeper understanding of the molecular biology of the ... vaccines or antiviral drugs to treat or prevent Ebola ... Virginia (UVA), USA under the leadership of Dr ... structural biologist has obtained the crystal structure of ...
(Date:9/15/2014)... cardiovascular disease (CVD) claims 17 million lives each year, ... 9.4 million. 1 New research presented by international ... Montpellier, France on September 15, 2014, suggests that milk ... , At the Milk and Dairy Products in ... risk for hypertension and CVD was examined by Dr. ...
Breaking Biology News(10 mins):Protein secrets of Ebola virus 2Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2
... join the two copies of each chromosomecalled sister chromatidsto ... cells during cell division. In this way, each daughter ... parent cell. Pds5 is a protein associated with ... vertebrates there are two variants of Pds5, Pds5A and ...
... industrial cities is often an overlooked resource. Years of manufacturing ... and scare residents away from using the land. As the ... the desire to grow food in cities with the fear ... at 10:35 am, Kristen McIvor of the Pierce Conservation District ...
... Zhang, a biochemist and geneticist with Texas A&M AgriLife ... million from the National Science Foundation to further his ... ultimately could help breed more productive plants. The ... is given in "support of junior faculty who exemplify ...
Cached Biology News:CNIO researchers delve into the behavior of cohesins 2Fostering community gardens in an area with historic soil contamination 2AgriLife researcher Xiuren Zhang receives National Science Foundation CAREER grant 2
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
...
...
...
Biology Products: